Technical Analysis for GDTC - CytoMed Therapeutics Limited

Grade Last Price % Change Price Change
F 3.41 -1.29% -0.04
GDTC closed down 1.29 percent on Friday, December 8, 2023, on 1.39 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Inside Day Range Contraction -1.29%
Gapped Up Strength -1.29%
Down 3 Days in a Row Weakness -1.29%
Oversold Stochastic Weakness -1.29%
Stochastic Buy Signal Bullish -2.01%
Volume Surge Other -2.01%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
Possible NR7 1 day ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


CytoMed Therapeutics Limited Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immune System Immunotherapy Cancer Treatment Immunotherapies Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Lymphocytes T Cells Human Cancers Pre Clinical Biopharmaceutical

Is GDTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.25
52 Week Low 2.36
Average Volume 5,732
200-Day Moving Average 0.00
50-Day Moving Average 3.67
20-Day Moving Average 3.72
10-Day Moving Average 3.57
Average True Range 0.17
RSI (14) 36.31
ADX 25.63
+DI 11.22
-DI 30.98
Chandelier Exit (Long, 3 ATRs) 3.76
Chandelier Exit (Short, 3 ATRs) 3.85
Upper Bollinger Bands 4.13
Lower Bollinger Band 3.31
Percent B (%b) 0.12
BandWidth 21.94
MACD Line -0.08
MACD Signal Line -0.04
MACD Histogram -0.0429
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.66
Resistance 3 (R3) 3.67 3.58 3.62
Resistance 2 (R2) 3.58 3.52 3.58 3.61
Resistance 1 (R1) 3.50 3.48 3.45 3.49 3.59
Pivot Point 3.41 3.41 3.39 3.41 3.41
Support 1 (S1) 3.33 3.35 3.29 3.33 3.23
Support 2 (S2) 3.24 3.31 3.24 3.21
Support 3 (S3) 3.16 3.24 3.20
Support 4 (S4) 3.16